Loading...
Header Logo
Keywords
Last Name
Institution

THOMAS COOPER

TitleProfessor
InstitutionBaylor College of Medicine
DepartmentDepartment of Pathology & Immunology
DivisionPathology
Email
vCardDownload vCard
    Other Positions
    TitleProfessor
    InstitutionBaylor College of Medicine
    DepartmentDepartment of Molecular & Cellular Biology
    DivisionMolecular & Cellular Biology

    TitleProfessor
    InstitutionBaylor College of Medicine
    DepartmentDepartment of Molecular Physiology & Biophysics
    DivisionMolecular Physiology & Biophysics


    Collapse ORNG Applications 
    Collapse Websites
    Collapse Faculty Mentor
    Collapse Aliases
    Collapse Verify Publications

    Collapse Biography 
    Collapse awards and honors
    1981 - 1982NIH Medical Research Trainee predoctoral award, University of California, San Francisco
    1982 - 1985NIH NRSA Postdoctoral Fellowship, University of California, San Francisco
    1985 - 1986Bank of America Giannini Foundation Postdoctoral Award, University of California, San Francisco
    1991 - 1994March of Dimes Basil O'Connor Starter Scholar Research Award, Baylor College of Medicine
    1992 - 1997Established Investigator Award, American Heart Association, Baylor College of Medicine
    1998Michael E. DeBakey, M.D. Excellence in Research Award, Baylor College of Medicine
    2003S. Donald Greenberg Endowed Chair, Baylor College of Medicine
    2014Michael E. DeBakey, M.D. Excellence in Research Award, Baylor College of Medicine
    2015R. Clarence and Irene H. Fulbright Endowed Chair, Baylor College of Medicine

    Collapse Overview 
    Collapse overview
    See our lab webpage: https://www.bcm.edu/research/labs/tom-cooper/?PMID=14453
    The realization that most human genes generate multiple mRNAs encoding different protein isoforms and variable untranslated regions via alternative splicing and alternative polyadenylation has revealed an extensive degree of regulation that remains to be explored.

    The Cooper Lab is interested in understanding the mechanisms of this regulation, from how RNA binding proteins regulate splicing of individual pre-mRNAs to the signaling events that coordinate RNA processing networks during development.

    A second major interest in the lab is the pathogenic mechanism of myotonic dystrophy in which disruption of developmentally regulated RNA processing causes primary features of the disease. Mechanistic understanding of myotonic dystrophy has led to development of therapeutic approaches being testing using mouse models established in the lab.

    Collapse Research 
    Collapse research activities and funding
    T32GM008231     (NELSON, DAVID LOREN)Jul 1, 1990 - Jun 30, 2020
    NIH/NIGMS
    Training Program in Cell and Molecular Biology
    Role: Co-Principal Investigator

    R29HL045565     (COOPER, THOMAS ALEXANDER)Jan 1, 1991 - Jul 16, 1996
    NIH/NHLBI
    TROPONIN T ALTERNATIVE SPLICING IN EMBRYONIC HEART
    Role: Principal Investigator

    R01HL045565     (COOPER, THOMAS A)Jul 1, 1991 - Nov 30, 2018
    NIH/NHLBI
    Troponin T Alternative Splicing in Embryonic Heart
    Role: Principal Investigator

    R01AR045653     (COOPER, THOMAS A)Feb 8, 1999 - Aug 31, 2019
    NIH/NIAMS
    Molecular Pathogenesis of Myotonic Dystrophy
    Role: Principal Investigator

    R01GM076493     (COOPER, THOMAS ALEXANDER)Feb 1, 2006 - Jul 31, 2011
    NIH/NIGMS
    Mechanisms of Developmentally Regulated Splicing
    Role: Principal Investigator

    RC2HG005624     (BURGE, CHRISTOPHER B)Sep 30, 2009 - Aug 31, 2012
    NIH/NHGRI
    Deep Sequencing Analysis of mRNA Isoform Expression Changes in Myotonic Dystrophy
    Role: Co-Principal Investigator

    R01AR060733     (COOPER, THOMAS A)Apr 1, 2011 - Feb 29, 2024
    NIH/NIAMS
    Transcriptome processing networks in skeletal muscle: mechanisms and functions
    Role: Principal Investigator

    R01HL147020     (COOPER, THOMAS A)Apr 15, 2019 - Mar 31, 2023
    NIH/NHLBI
    Pathogenic mechanisms and therapeutics for the cardiac manifestations of myotonic dystrophy type 1
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Payer LM, Steranka JP, Ardeljan D, Walker J, Fitzgerald KC, Calabresi PA, Cooper TA, Burns KH. Alu insertion variants alter mRNA splicing. Nucleic Acids Res. 2019 Jan 10; 47(1):421-431. PMID: 30418605.
      View in: PubMed
    2. Blue RE, Koushik A, Engels NM, Wiedner HJ, Cooper TA, Giudice J. Modulation of alternative splicing of trafficking genes by genome editing reveals functional consequences in muscle biology. Int J Biochem Cell Biol. 2018 12; 105:134-143. PMID: 30316870.
      View in: PubMed
    3. Pang PD, Alsina KM, Cao S, Koushik AB, Wehrens XHT, Cooper TA. CRISPR -Mediated Expression of the Fetal Scn5a Isoform in Adult Mice Causes Conduction Defects and Arrhythmias. J Am Heart Assoc. 2018 Oct 02; 7(19):e010393. PMID: 30371314.
      View in: PubMed
    4. Morriss GR, Rajapakshe K, Huang S, Coarfa C, Cooper TA. Mechanisms of skeletal muscle wasting in a mouse model for myotonic dystrophy type 1. Hum Mol Genet. 2018 08 15; 27(16):2789-2804. PMID: 29771332.
      View in: PubMed
    5. Singh RK, Kolonin AM, Fiorotto ML, Cooper TA. Rbfox-Splicing Factors Maintain Skeletal Muscle Mass by Regulating Calpain3 and Proteostasis. Cell Rep. 2018 Jul 03; 24(1):197-208. PMID: 29972780.
      View in: PubMed
    6. Rao AN, Cooper TA. A Therapeutic Double Whammy: Transcriptional or Post-transcriptional Suppression of Microsatellite Repeat Toxicity by Cas9. Mol Cell. 2017 11 02; 68(3):473-475. PMID: 29100050.
      View in: PubMed
    7. Brinegar AE, Xia Z, Loehr JA, Li W, Rodney GG, Cooper TA. Extensive alternative splicing transitions during postnatal skeletal muscle development are required for calcium handling functions. Elife. 2017 08 11; 6. PMID: 28826478.
      View in: PubMed
    8. Sharpe JJ, Cooper TA. Unexpected consequences: exon skipping caused by CRISPR-generated mutations. Genome Biol. 2017 06 14; 18(1):109. PMID: 28615035.
      View in: PubMed
    9. Morriss GR, Cooper TA. Protein sequestration as a normal function of long noncoding RNAs and a pathogenic mechanism of RNAs containing nucleotide repeat expansions. Hum Genet. 2017 09; 136(9):1247-1263. PMID: 28484853.
      View in: PubMed
    10. Manning KS, Cooper TA. The roles of RNA processing in translating genotype to phenotype. Nat Rev Mol Cell Biol. 2017 02; 18(2):102-114. PMID: 27847391.
      View in: PubMed
    11. Giudice J, Loehr JA, Rodney GG, Cooper TA. Alternative Splicing of Four Trafficking Genes Regulates Myofiber Structure and Skeletal Muscle Physiology. Cell Rep. 2016 11 15; 17(8):1923-1933. PMID: 27851958.
      View in: PubMed
    12. Giudice J, Xia Z, Li W, Cooper TA. Neonatal cardiac dysfunction and transcriptome changes caused by the absence of Celf1. Sci Rep. 2016 10 19; 6:35550. PMID: 27759042.
      View in: PubMed
    13. Cox DC, Cooper TA. Non-canonical RAN Translation of CGG Repeats Has Canonical Requirements. Mol Cell. 2016 04 21; 62(2):155-156. PMID: 27105111.
      View in: PubMed
    14. Brinegar AE, Cooper TA. Roles for RNA-binding proteins in development and disease. Brain Res. 2016 09 15; 1647:1-8. PMID: 26972534.
      View in: PubMed
    15. Hsu TY, Simon LM, Neill NJ, Marcotte R, Sayad A, Bland CS, Echeverria GV, Sun T, Kurley SJ, Tyagi S, Karlin KL, Dominguez-Vidaña R, Hartman JD, Renwick A, Scorsone K, Bernardi RJ, Skinner SO, Jain A, Orellana M, Lagisetti C, Golding I, Jung SY, Neilson JR, Zhang XH, Cooper TA, Webb TR, Neel BG, Shaw CA, Westbrook TF. The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature. 2015 Sep 17; 525(7569):384-8. PMID: 26331541.
      View in: PubMed
    16. Jaiswal M, Haelterman NA, Sandoval H, Xiong B, Donti T, Kalsotra A, Yamamoto S, Cooper TA, Graham BH, Bellen HJ. Impaired Mitochondrial Energy Production Causes Light-Induced Photoreceptor Degeneration Independent of Oxidative Stress. PLoS Biol. 2015 Jul; 13(7):e1002197. PMID: 26176594.
      View in: PubMed
    17. Wang ET, Ward AJ, Cherone JM, Giudice J, Wang TT, Treacy DJ, Lambert NJ, Freese P, Saxena T, Cooper TA, Burge CB. \Antagonistic regulation of mRNA expression and splicing by CELF and MBNL proteins. Genome Res. 2015; 25(6):858-71.
    18. Wang ET, Ward AJ, Cherone JM, Giudice J, Wang TT, Treacy DJ, Lambert NJ, Freese P, Saxena T, Cooper TA, Burge CB. Antagonistic regulation of mRNA expression and splicing by CELF and MBNL proteins. Genome Res. 2015 Jun; 25(6):858-71. PMID: 25883322.
      View in: PubMed
    19. Gennarino VA, Singh RK, White JJ, De Maio A, Han K, Kim JY, Jafar-Nejad P, di Ronza A, Kang H, Sayegh LS, Cooper TA, Orr HT, Sillitoe RV, Zoghbi HY. Pumilio1 haploinsufficiency leads to SCA1-like neurodegeneration by increasing wild-type Ataxin1 levels. Cell. 2015 Mar 12; 160(6):1087-98. PMID: 25768905.
      View in: PubMed
    20. Xia Z, Donehower LA, Cooper TA, Neilson JR, Wheeler DA, Wagner EJ, Li W. Dynamic analyses of alternative polyadenylation from RNA-seq reveal a 3'-UTR landscape across seven tumour types. Nat Commun. 2014 Nov 20; 5:5274. PMID: 25409906.
      View in: PubMed
    21. Singh RK, Xia Z, Bland CS, Kalsotra A, Scavuzzo MA, Curk T, Ule J, Li W, Cooper TA. Rbfox2-coordinated alternative splicing of Mef2d and Rock2 controls myoblast fusion during myogenesis. Mol Cell. 2014 Aug 21; 55(4):592-603. PMID: 25087874.
      View in: PubMed
    22. Pedrotti S, Cooper TA. In Brief: (mis)splicing in disease. J Pathol. 2014 May; 233(1):1-3. PMID: 24615176.
      View in: PubMed
    23. Giudice J, Xia Z, Wang ET, Scavuzzo MA, Ward AJ, Kalsotra A, Wang W, Wehrens XH, Burge CB, Li W, Cooper TA. Alternative splicing regulates vesicular trafficking genes in cardiomyocytes during postnatal heart development. Nat Commun. 2014 Apr 22; 5:3603. PMID: 24752171.
      View in: PubMed
    24. Kalsotra A, Singh RK, Gurha P, Ward AJ, Creighton CJ, Cooper TA. The Mef2 transcription network is disrupted in myotonic dystrophy heart tissue, dramatically altering miRNA and mRNA expression. Cell Rep. 2014 Jan 30; 6(2):336-45. PMID: 24412363.
      View in: PubMed
    25. Echeverria GV, Cooper TA. Muscleblind-like 1 activates insulin receptor exon 11 inclusion by enhancing U2AF65 binding and splicing of the upstream intron. Nucleic Acids Res. 2014; 42(3):1893-903.
    26. Giudice J, Cooper TA. RNA-binding proteins in heart development. Adv Exp Med Biol. 2014; 825:389-429. PMID: 25201112.
      View in: PubMed
    27. Echeverria GV, Cooper TA. Muscleblind-like 1 activates insulin receptor exon 11 inclusion by enhancing U2AF65 binding and splicing of the upstream intron. Nucleic Acids Res. 2014 Feb; 42(3):1893-903. PMID: 24185704.
      View in: PubMed
    28. Gao Z, Cooper TA. Reexpression of pyruvate kinase M2 in type 1 myofibers correlates with altered glucose metabolism in myotonic dystrophy. Proc Natl Acad Sci U S A. 2013 Aug 13; 110(33):13570-5. PMID: 23901116.
      View in: PubMed
    29. Gao Z, Cooper TA. Antisense oligonucleotides: rising stars in eliminating RNA toxicity in myotonic dystrophy. Hum Gene Ther. 2013 May; 24(5):499-507. PMID: 23252746.
      View in: PubMed
    30. Cooper TA. Implications of widespread covalent modification of mRNA. Circ Res. 2012 Dec 07; 111(12):1491-3. PMID: 23223930.
      View in: PubMed
    31. Singh RK, Cooper TA. Pre-mRNA splicing in disease and therapeutics. Trends Mol Med. 2012 Aug; 18(8):472-82. PMID: 22819011.
      View in: PubMed
    32. Lee JE, Bennett CF, Cooper TA. RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1. Proc Natl Acad Sci U S A. 2012 Mar 13; 109(11):4221-6. PMID: 22371589.
      View in: PubMed
    33. Echeverria GV, Cooper TA. RNA-binding proteins in microsatellite expansion disorders: mediators of RNA toxicity. Brain Res. 2012 Jun 26; 1462:100-11. PMID: 22405728.
      View in: PubMed
    34. Kalsotra A, Cooper TA. Functional consequences of developmentally regulated alternative splicing. Nat Rev Genet. 2011 Sep 16; 12(10):715-29. PMID: 21921927.
      View in: PubMed
    35. Orengo JP, Ward AJ, Cooper TA. Alternative splicing dysregulation secondary to skeletal muscle regeneration. Ann Neurol. 2011 Apr; 69(4):681-90. PMID: 21400563.
      View in: PubMed
    36. Meerbrey KL, Hu G, Kessler JD, Roarty K, Li MZ, Fang JE, Herschkowitz JI, Burrows AE, Ciccia A, Sun T, Schmitt EM, Bernardi RJ, Fu X, Bland CS, Cooper TA, Schiff R, Rosen JM, Westbrook TF, Elledge SJ. The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc Natl Acad Sci U S A. 2011 Mar 01; 108(9):3665-70. PMID: 21307310.
      View in: PubMed
    37. Grammatikakis I, Goo YH, Echeverria GV, Cooper TA. Identification of MBNL1 and MBNL3 domains required for splicing activation and repression. Nucleic Acids Res. 2011 Apr; 39(7):2769-80. PMID: 21109529.
      View in: PubMed
    38. Bland CS, Wang ET, Vu A, David MP, Castle JC, Johnson JM, Burge CB, Cooper TA. Global regulation of alternative splicing during myogenic differentiation. Nucleic Acids Res. 2010 Nov; 38(21):7651-64. PMID: 20634200.
      View in: PubMed
    39. Ward AJ, Rimer M, Killian JM, Dowling JJ, Cooper TA. CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1. Hum Mol Genet. 2010 Sep 15; 19(18):3614-22. PMID: 20603324.
      View in: PubMed
    40. Kalsotra A, Wang K, Li PF, Cooper TA. MicroRNAs coordinate an alternative splicing network during mouse postnatal heart development. Genes Dev. 2010 Apr 01; 24(7):653-8. PMID: 20299448.
      View in: PubMed
    41. Koshelev M, Sarma S, Price RE, Wehrens XH, Cooper TA. Heart-specific overexpression of CUGBP1 reproduces functional and molecular abnormalities of myotonic dystrophy type 1. Hum Mol Genet. 2010 Mar 15; 19(6):1066-75. PMID: 20051426.
      View in: PubMed
    42. Ward AJ, Cooper TA. The pathobiology of splicing. J Pathol. 2010 Jan; 220(2):152-63. PMID: 19918805.
      View in: PubMed
    43. Lee JE, Cooper TA. Pathogenic mechanisms of myotonic dystrophy. Biochem Soc Trans. 2009 Dec; 37(Pt 6):1281-6. PMID: 19909263.
      View in: PubMed
    44. Wang GS, Kuyumcu-Martinez MN, Sarma S, Mathur N, Wehrens XH, Cooper TA. PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1. J Clin Invest. 2009 Dec; 119(12):3797-806. PMID: 19907076.
      View in: PubMed
    45. Cooper TA. Chemical reversal of the RNA gain of function in myotonic dystrophy. Proc Natl Acad Sci U S A. 2009 Nov 03; 106(44):18433-4. PMID: 19864622.
      View in: PubMed
    46. Cooper TA. Molecular biology. Neutralizing toxic RNA. Science. 2009 Jul 17; 325(5938):272-3. PMID: 19608901.
      View in: PubMed
    47. Goo YH, Cooper TA. CUGBP2 directly interacts with U2 17S snRNP components and promotes U2 snRNA binding to cardiac troponin T pre-mRNA. Nucleic Acids Res. 2009 Jul; 37(13):4275-86. PMID: 19443441.
      View in: PubMed
    48. Cooper TA, Wan L, Dreyfuss G. RNA and disease. Cell. 2009 Feb 20; 136(4):777-93. PMID: 19239895.
      View in: PubMed
    49. Kalsotra A, Xiao X, Ward AJ, Castle JC, Johnson JM, Burge CB, Cooper TA. A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart. Proc Natl Acad Sci U S A. 2008 Dec 23; 105(51):20333-8. PMID: 19075228.
      View in: PubMed
    50. Orengo JP, Chambon P, Metzger D, Mosier DR, Snipes GJ, Cooper TA. Expanded CTG repeats within the DMPK 3' UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy. Proc Natl Acad Sci U S A. 2008 Feb 19; 105(7):2646-51. PMID: 18272483.
      View in: PubMed
    51. Dhaenens CM, Schraen-Maschke S, Tran H, Vingtdeux V, Ghanem D, Leroy O, Delplanque J, Vanbrussel E, Delacourte A, Vermersch P, Maurage CA, Gruffat H, Sergeant A, Mahadevan MS, Ishiura S, Buée L, Cooper TA, Caillet-Boudin ML, Charlet-Berguerand N, Sablonnière B, Sergeant N. Overexpression of MBNL1 fetal isoforms and modified splicing of Tau in the DM1 brain: two individual consequences of CUG trinucleotide repeats. Exp Neurol. 2008 Apr; 210(2):467-78. PMID: 18177861.
      View in: PubMed
    52. Kuyumcu-Martinez NM, Wang GS, Cooper TA. Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell. 2007 Oct 12; 28(1):68-78. PMID: 17936705.
      View in: PubMed
    53. Wang GS, Kearney DL, De Biasi M, Taffet G, Cooper TA. Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy. J Clin Invest. 2007 Oct; 117(10):2802-11. PMID: 17823658.
      View in: PubMed
    54. Wang GS, Cooper TA. Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet. 2007 Oct; 8(10):749-61. PMID: 17726481.
      View in: PubMed
    55. Bland CS, Cooper TA. Micromanaging alternative splicing during muscle differentiation. Dev Cell. 2007 Feb; 12(2):171-2. PMID: 17276332.
      View in: PubMed
    56. Orengo JP, Cooper TA. Alternative splicing in disease. Adv Exp Med Biol. 2007; 623:212-23. PMID: 18380349.
      View in: PubMed
    57. Orengo JP, Bundman D, Cooper TA. A bichromatic fluorescent reporter for cell-based screens of alternative splicing. Nucleic Acids Res. 2006; 34(22):e148. PMID: 17142220.
      View in: PubMed
    58. Cooper TA. A reversal of misfortune for myotonic dystrophy? N Engl J Med. 2006 Oct 26; 355(17):1825-7. PMID: 17065646.
      View in: PubMed
    59. Singh G, Cooper TA. Minigene reporter for identification and analysis of cis elements and trans factors affecting pre-mRNA splicing. Biotechniques. 2006 Aug; 41(2):177-81. PMID: 16925019.
      View in: PubMed
    60. de Haro M, Al-Ramahi I, De Gouyon B, Ukani L, Rosa A, Faustino NA, Ashizawa T, Cooper TA, Botas J. MBNL1 and CUGBP1 modify expanded CUG-induced toxicity in a Drosophila model of myotonic dystrophy type 1. Hum Mol Genet. 2006 Jul 01; 15(13):2138-45. PMID: 16723374.
      View in: PubMed
    61. Kuyumcu-Martinez NM, Cooper TA. Misregulation of alternative splicing causes pathogenesis in myotonic dystrophy. Prog Mol Subcell Biol. 2006; 44:133-59. PMID: 17076268.
      View in: PubMed
    62. Cooper TA. Use of minigene systems to dissect alternative splicing elements. Methods. 2005 Dec; 37(4):331-40. PMID: 16314262.
      View in: PubMed
    63. Ladd AN, Taffet G, Hartley C, Kearney DL, Cooper TA. Cardiac tissue-specific repression of CELF activity disrupts alternative splicing and causes cardiomyopathy. Mol Cell Biol. 2005 Jul; 25(14):6267-78. PMID: 15988035.
      View in: PubMed
    64. Ladd AN, Stenberg MG, Swanson MS, Cooper TA. Dynamic balance between activation and repression regulates pre-mRNA alternative splicing during heart development. Dev Dyn. 2005 Jul; 233(3):783-93. PMID: 15830352.
      View in: PubMed
    65. Ho TH, Savkur RS, Poulos MG, Mancini MA, Swanson MS, Cooper TA. Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy. J Cell Sci. 2005 Jul 01; 118(Pt 13):2923-33. PMID: 15961406.
      View in: PubMed
    66. Han J, Cooper TA. Identification of CELF splicing activation and repression domains in vivo. Nucleic Acids Res. 2005; 33(9):2769-80. PMID: 15894795.
      View in: PubMed
    67. Ho TH, Bundman D, Armstrong DL, Cooper TA. Transgenic mice expressing CUG-BP1 reproduce splicing mis-regulation observed in myotonic dystrophy. Hum Mol Genet. 2005 Jun 01; 14(11):1539-47. PMID: 15843400.
      View in: PubMed
    68. Faustino NA, Cooper TA. Identification of putative new splicing targets for ETR-3 using sequences identified by systematic evolution of ligands by exponential enrichment. Mol Cell Biol. 2005 Feb; 25(3):879-87. PMID: 15657417.
      View in: PubMed
    69. Cooper TA. Alternative splicing regulation impacts heart development. Cell. 2005 Jan 14; 120(1):1-2. PMID: 15652472.
      View in: PubMed
    70. Ho TH, Charlet-B N, Poulos MG, Singh G, Swanson MS, Cooper TA. Muscleblind proteins regulate alternative splicing. EMBO J. 2004 Aug 04; 23(15):3103-12. PMID: 15257297.
      View in: PubMed
    71. Ladd AN, Cooper TA. Multiple domains control the subcellular localization and activity of ETR-3, a regulator of nuclear and cytoplasmic RNA processing events. J Cell Sci. 2004 Jul 15; 117(Pt 16):3519-29. PMID: 15226369.
      View in: PubMed
    72. Savkur RS, Philips AV, Cooper TA, Dalton JC, Moseley ML, Ranum LP, Day JW. Insulin receptor splicing alteration in myotonic dystrophy type 2. Am J Hum Genet. 2004 Jun; 74(6):1309-13. PMID: 15114529.
      View in: PubMed
    73. Singh G, Charlet-B N, Han J, Cooper TA. ETR-3 and CELF4 protein domains required for RNA binding and splicing activity in vivo. Nucleic Acids Res. 2004; 32(3):1232-41. PMID: 14973222.
      View in: PubMed
    74. Ladd AN, Nguyen NH, Malhotra K, Cooper TA. CELF6, a member of the CELF family of RNA-binding proteins, regulates muscle-specific splicing enhancer-dependent alternative splicing. J Biol Chem. 2004 Apr 23; 279(17):17756-64. PMID: 14761971.
      View in: PubMed
    75. Faustino NA, Cooper TA. Pre-mRNA splicing and human disease. Genes Dev. 2003 Feb 15; 17(4):419-37. PMID: 12600935.
      View in: PubMed
    76. Ladd AN, Cooper TA. Finding signals that regulate alternative splicing in the post-genomic era. Genome Biol. 2002 Oct 23; 3(11):reviews0008. PMID: 12429065.
      View in: PubMed
    77. Charlet-B N, Savkur RS, Singh G, Philips AV, Grice EA, Cooper TA. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol Cell. 2002 Jul; 10(1):45-53. PMID: 12150906.
      View in: PubMed
    78. Charlet-B N, Logan P, Singh G, Cooper TA. Dynamic antagonism between ETR-3 and PTB regulates cell type-specific alternative splicing. Mol Cell. 2002 Mar; 9(3):649-58. PMID: 11931771.
      View in: PubMed
    79. Timchenko LT, Tapscott SJ, Cooper TA, Monckton DG. Myotonic dystrophy: discussion of molecular basis. Adv Exp Med Biol. 2002; 516:27-45. PMID: 12611434.
      View in: PubMed
    80. Stickeler E, Fraser SD, Honig A, Chen AL, Berget SM, Cooper TA. The RNA binding protein YB-1 binds A/C-rich exon enhancers and stimulates splicing of the CD44 alternative exon v4. EMBO J. 2001 Jul 16; 20(14):3821-30. PMID: 11447123.
      View in: PubMed
    81. Stark JM, Cooper TA, Roth MB. The relative strengths of SR protein-mediated associations of alternative and constitutive exons can influence alternative splicing. J Biol Chem. 1999 Oct 15; 274(42):29838-42. PMID: 10514463.
      View in: PubMed
    82. Stoss O, Schwaiger FW, Cooper TA, Stamm S. Alternative splicing determines the intracellular localization of the novel nuclear protein Nop30 and its interaction with the splicing factor SRp30c. J Biol Chem. 1999 Apr 16; 274(16):10951-62. PMID: 10196175.
      View in: PubMed
    COOPER's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description